Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 44
- Locations
- 1
- Primary Endpoint
- Viability on primary ALL samples
Study Overview
Brief Summary
NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient suffering from acute lymphoblastic leukaemia whose biological samples are kept at the Biology Technical Platform.
Exclusion Criteria
- •Patient over 80 years of age
Arms & Interventions
T-ALL
Intervention: injection of BEP 800 (Drug)
T-ALL
Intervention: Control (Other)
B-ALL
Intervention: injection of BEP 800 (Drug)
B-ALL
Intervention: Control (Other)
Outcomes
Primary Outcomes
Viability on primary ALL samples
Time Frame: 2 years
The effect of BEP-800 after 48 hours of treatment on T-ALL and B-ALL will be evaluated by counting viable cells by flow cytometry with a viability marker and specific antibodies to detect leukemia cells.
Secondary Outcomes
- Effect on SRC phosphorylation(2 years)